Xcelent Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 16 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.15 M
- Revenue Growth 68.72%
- Profit Growth 233.51%
- Ebitda 2383.97%
- Net Worth 65.07%
- Total Assets 71.73%
About Xcelent Pharmaceuticals
Xcelent Pharmaceuticals Private Limited (XPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 30 January 2021 (Four years 16 days old ). Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.15 M.
Premlata Rastogi, Ram Rastogi, and Shikha Sharma serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230UP2021PTC140979
-
Company No.
140979
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Jan 2021
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Xcelent Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Premlata Rastogi
|
Director | 30-Jan-2021 | Current |
|
Ram Rastogi
|
Director | 30-Jan-2021 | Current |
|
Shikha Sharma
|
Director | 12-Aug-2023 | Current |
Financial Performance of Xcelent Pharmaceuticals.
Xcelent Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.72% increase. The company also saw a substantial improvement in profitability, with a 233.51% increase in profit. The company's net worth Soared by an impressive increase of 65.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xcelent Pharmaceuticals?
Unlock access to Xcelent Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.15 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Mar 2024 | State Bank Of India | ₹2.15 M | Open |
How Many Employees Work at Xcelent Pharmaceuticals?
Unlock and access historical data on people associated with Xcelent Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xcelent Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xcelent Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
